Impressive Growth Leads to Expansion at Biotec Services
Biotec Services International, the global provider of temperature-controlled packaging and distribution services for clinical trials, is doubling its capacity with the addition of new processing facilities, following impressive growth.
The UK-headquartered company is expanding into additional operational, packaging and storage facilities on the back of 15% growth in the last year.
As a result of increased client demand, which includes a new contract win worth £5 million, Biotec Services is increasing its controlled room temperature storage by 100 per cent and its cold room storage by 400%. It is also creating a second advanced therapeutic medicinal products (ATMP) facility.
Providing support to hundreds of clinical trial and commercial projects for clients across the world, Biotec Services has built an impressive reputation for its cold chain packaging and distribution services across a full temperature range from controlled ambient down to minus 196 °C.
Dr Fiona Withey, CEO, said: “We have an exciting pipeline of work and an increasing number of Phase III trials with larger storage requirements, which has resulted in a need to expand our temperature controlled packaging and storage facilities.
“Feedback from our recent client survey indicated that refrigerated storage at +2 °C to +8 °C is the range that most suits our partners’ requirements so we are developing our facilities in line with this and also bespoke temperature demands.
“The investment demonstrates our continued commitment to developing innovative solutions to meet our clients’ clinical supplies requirements.”
As part of the company’s strategic growth plans, it has also acquired land adjacent to the current Biotec Services’ facilities, which will be developed in-line with client demands.
Dr Withey, continued: “We have ambitious objectives for the next 3 years as we move towards achieving our vision of becoming the market leader in cold chain clinical trial services, headquartered in the UK with a global presence. We will be looking to continue to develop our services for existing customers and to grow more and more partnerships worldwide, tackling new markets. With these plans in mind, we have secured land adjoining our current facilities to accommodate our future growth.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.